{"id":"dha-ppq","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"QT prolongation (piperaquine-related)"}]},"_chembl":{"chemblId":"CHEMBL263499","moleculeType":"Small molecule","molecularWeight":"1164.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dihydroartemisinin (DHA), a semi-synthetic artemisinin derivative, rapidly reduces parasite biomass through oxidative stress mechanisms. Piperaquine, a bisquinoline, accumulates in parasite food vacuoles and inhibits heme detoxification. Together, they provide synergistic antimalarial activity with rapid parasite clearance and extended post-treatment suppression.","oneSentence":"DHA-PPQ is a fixed-dose combination of dihydroartemisinin and piperaquine that kills malaria parasites by generating reactive oxygen species and disrupting parasite metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:20.785Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by Plasmodium vivax and other Plasmodium species"}]},"trialDetails":[{"nctId":"NCT07403643","phase":"PHASE4","title":"Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria","status":"NOT_YET_RECRUITING","sponsor":"Curtin University","startDate":"2026-04","conditions":"Uncomplicated Malaria","enrollment":60},{"nctId":"NCT06347471","phase":"PHASE4","title":"The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy","status":"RECRUITING","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2024-05-28","conditions":"Falciparum; Malaria","enrollment":120},{"nctId":"NCT03671109","phase":"PHASE3","title":"Improving Maternal heAlth by Reducing Malaria in African HIV Women","status":"COMPLETED","sponsor":"Barcelona Institute for Global Health","startDate":"2019-09-18","conditions":"Malaria, HIV/AIDS, Pregnancy Related","enrollment":666},{"nctId":"NCT04864444","phase":"NA","title":"Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-06-19","conditions":"Malaria,Falciparum, Malaria","enrollment":10715},{"nctId":"NCT04767217","phase":"PHASE4","title":"Malaria Therapeutic Efficacy Study, Rwanda","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2021-06-14","conditions":"Uncomplicated Malaria","enrollment":528},{"nctId":"NCT01640587","phase":"NA","title":"Compare the Effectiveness Between Existing Treatment and New Treatment","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2013-11","conditions":"P. Falciparum Malaria","enrollment":76},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511},{"nctId":"NCT04778813","phase":"PHASE4","title":"Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)","status":"UNKNOWN","sponsor":"Centre national de recherche et de formation sur le paludisme","startDate":"2021-06-01","conditions":"Malaria, Burkina Faso","enrollment":1050},{"nctId":"NCT02612545","phase":"PHASE1","title":"Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-20","conditions":"Acute Falciparum Malaria","enrollment":216},{"nctId":"NCT03697668","phase":"PHASE2","title":"Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites","status":"UNKNOWN","sponsor":"Nurex S.r.l.","startDate":"2017-09-17","conditions":"Plasmodium Falciparum Malaria (Drug Resistant)","enrollment":50},{"nctId":"NCT01736319","phase":"","title":"Artemisinin-resistant Malaria in Cambodia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06-26","conditions":"Plasmodium Falciparum Malaria","enrollment":561},{"nctId":"NCT00682578","phase":"PHASE3","title":"A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-07","conditions":"Uncomplicated Falciparum Malaria, Vivax Malaria","enrollment":1086},{"nctId":"NCT01838902","phase":"PHASE3","title":"Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-08","conditions":"Malaria","enrollment":467},{"nctId":"NCT02654730","phase":"PHASE2, PHASE3","title":"Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia","status":"TERMINATED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2015-12","conditions":"Malaria","enrollment":61},{"nctId":"NCT02605720","phase":"PHASE3","title":"Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2015-09","conditions":"Malaria","enrollment":78},{"nctId":"NCT02604966","phase":"PHASE4","title":"P. Falciparum Resistance to Artemisinin in Vietnam","status":"UNKNOWN","sponsor":"National Institute of Malariology, Parasitology and Entomology, Vietnam","startDate":"2015-04","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":120},{"nctId":"NCT01775592","phase":"PHASE4","title":"Plasmodium Falciparum Artemisinin Resistance Vietnam","status":"COMPLETED","sponsor":"National Institute of Malariology, Parasitology and Entomology, Vietnam","startDate":"2012-09","conditions":"Plasmodium Falciparum","enrollment":95},{"nctId":"NCT01165372","phase":"PHASE2","title":"Study of Malaria Treatment at Phuoc Long Hospital, Binh Phuoc Province, Vietnam","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2010-08","conditions":"Malaria","enrollment":166}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eurartesim"],"phase":"phase_3","status":"active","brandName":"DHA-PPQ","genericName":"DHA-PPQ","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DHA-PPQ is a fixed-dose combination of dihydroartemisinin and piperaquine that kills malaria parasites by generating reactive oxygen species and disrupting parasite metabolism. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax and other Plasmodium species.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}